Detail akcie Recordati online

Business Summary: Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Recordati Industria Chmc Frmctc SpA revenues increased 12% to EUR2.08B. Net income increased 25% to EUR389.2M. Revenues reflect Rare diseases segment increase of 20% to EUR714.7M, Specialty & Primary care segment increase of 9% to EUR1.37B, United States segment increase of 20% to EUR322.8M, Italy segment increase of 14% to EUR313.5M, Other international segment increase of 16% to EUR265.5M.